Developing drugs to target a key protein involved in brain signaling
Targeting Postsynaptic Small G-protein Regulators
This study is looking for new medicines that can help improve brain function by targeting a protein called kalirin, which is important for how our brain cells communicate, and it could lead to better treatments for conditions like depression and schizophrenia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10867469 on NIH RePORTER |
What this research studies
This research focuses on identifying and validating small-molecule inhibitors that target kalirin, a protein crucial for signaling in dendritic spines of the brain. By understanding how kalirin affects brain plasticity and its role in neuropsychiatric disorders, the researchers aim to develop new treatments for conditions like depression and schizophrenia. The approach involves studying the molecular pathways that govern brain function and how they can be manipulated to improve mental health. Patients may benefit from potential new therapies that arise from this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from neuropsychiatric disorders such as depression, schizophrenia, or other related conditions.
Not a fit: Patients with neuropsychiatric disorders not linked to dendritic spine dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for various neuropsychiatric disorders.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways for treating neuropsychiatric disorders, indicating a potential for success in this approach.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Penzes, Peter — Northwestern University at Chicago
- Study coordinator: Penzes, Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.